Bemnifosbuvir sulfate is under clinical development by Atea Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bemnifosbuvir sulfate’s likelihood of approval (LoA) and phase transition for Hepatitis C took place on 09 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bemnifosbuvir sulfate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bemnifosbuvir sulfate overview

AT-527 is under development for the treatment of chronic Hepatitis C viral infections and coronavirus COVID-19 disease. The drug candidate is a pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor. It is administered through oral route in the form of tablet. The drug candidate is developed based on purine nucleotide prodrug platform.

It was also under development for the treatment of coronavirus COVID-19 disease.

Atea Pharmaceuticals overview

Atea Pharmaceuticals (Atea) is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases including herpesvirus, hepatitis B, hepatitis C infections and HIV/AIDS. The company utilizes its purine nucleotide prodrug platform for the development of its products. Pipeline products of the company include AT527 for the treatment of COVID-19, AT-752 for dengue, AT-787 for Hepatitis C (HCV), AT-889 and AT-934 for the treatment of respiratory syncytial virus infection. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, the US.

Quick View Bemnifosbuvir sulfate LOA Data

Report Segments
  • Innovator
Drug Name
  • Bemnifosbuvir sulfate
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.